NCT04042103

Maximal Use Study of Tapinarof Cream, 1% in Adults With Extensive Plaque Psoriasis

Open-Label Maximal Use Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Tapinarof Cream, 1% in Adults With Extensive Plaque Psoriasis

• Status: Completed
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 21 (actual)
• Sponsor: Organon and Co · Industry
• Sex: All
• Age: 18 Years – 75 Years
• Healthy volunteers: Not accepted

Summary

This is an open-label, multicenter study to evaluate the systemic exposure and safety of topical tapinarof cream, 1% under conditions of maximal use in adults with plaque psoriasis.

Conditions

• Plaque Psoriasis

Interventions

Type	Name	Description
DRUG	Tapinarof cream, 1%	Tapinarof cream, 1% applied topically once daily

Timeline

• Start date: 2019-07-23
• Primary completion: 2020-01-09
• Completion: 2020-01-09
• First posted: 2019-08-01
• Last updated: 2025-06-19
• Results posted: 2022-05-06

Locations

6 sites across 1 country: United States

Regulatory

• FDA-regulated drug study